FDA Clears CTA-Based AI Software for Enhanced Visualization of Head and Neck Arteries

The Food and Drug Administration (FDA) has granted 510(k) clearance for NeuroDR, an AI-enabled software that may offer improved visualization of head and neck arteries based on computed tomography angiography (CTA) scans.

After the NeuroDR software removes bone, soft tissue and veins from CTA scans, the adjunctive AI software provides automated 3D maximum intensity projection (MIP) views, 3D volume renderings and curved planar reformatted images of internal carotid and vertebral arteries, according to Deep Reasoning AI, the developer of NeuroDR.

Deep Reasoning AI also points out that NeuroDR has the capability of providing separate views of anterior and posterior circulation without overlapping anatomy.

“NeuroDR is Deep Reasoning AI's first FDA-cleared product and a first step toward complete, patient-specific 3D anatomy from routine scans,” said Mike Beck, the president and CEO of Deep Reasoning AI.